Massive Bio teams up with Biden Cancer Initiative to boost oncology clinical trials access

5th June 2019 (Last Updated June 5th, 2019 15:56)

Massive Bio, a US-based provider of precision medicine and patient centric clinical trial matching services, has partnered in the Biden Cancer Initiative’s Oncology Clinical Trial Information Commons (OCTIC).

Massive Bio teams up with Biden Cancer Initiative to boost oncology clinical trials access
Massive Bio’s Hub is aimed at increasing access to oncology clinical trials. Credit: Marcelo Leal on Unsplash.

Massive Bio, a US-based provider of precision medicine and patient centric clinical trial matching services, has partnered in the Biden Cancer Initiative’s Oncology Clinical Trial Information Commons (OCTIC).

The partnership is aimed at increasing access to oncology clinical trials.

The founding members of OCTIC platform include healthcare organisations namely BreastCancerTrials.org, IBM Watson Health, Massive Bio and Syapse.

OCTIC is a shared platform that allows information about clinical trials including patient selection criteria and patient participation details to be stored and accessed for patient matching and other data mining purposes.

Through a single set of terms and rules and a user-friendly interface, the system enables biopharmaceutical companies to enter and update their trials.

Massive Bio co-founder and CEO Selin Kurnaz said: “Massive Bio is excited to work with the Biden Cancer Initiative and other healthcare innovators to eliminate redundancy in oncology clinical trials. More specifically how the information should be entered, stored and accessed for patient matching and other data mining in clinical trial protocols at ClinicalTrials.Gov.

“Like every other healthcare company, we spend a significant amount of time to structure and correct the information in ClinicalTrials.Gov with our proprietary technology. We have constant interactions with pharmaceutical companies and CROs to keep information complete and current.”

Massive Bio co-founder and chief medical advisor Arturo Loaiza-Bonilla said: “At Massive Bio we are very proud and excited to be part of this founding collaboration powered by the Clinical Trials Acceleration team from the Biden Cancer Initiative, which includes the most innovative and cutting-edge institutions and technology companies from around the US, working as a team to improve access to clinical trials for every patient, everywhere.

“By joining the OCTIC, we look forward to bringing our Artificial Intelligence (AI) enabled precision oncology expertise and patient-centered perspective to advance cancer research further and to forge a new era of making clinical trials accessible and readily available to all.”

By partnering with the Biden Cancer Initiative and other healthcare innovators, Massive Bio aims to speed up and amplify positive impact to cancer patients.